Announcement PDF CRAIG NEWTON TO TRANSITION TO INVION CEO DR GREG COLLIER TO RETIRE AS MD AND CEO, REMAIN AS NED MELBOURNE (AUSTRALIA) 22 JULY 2019: Cancer drug developer Invion Limited (ASX: IVX) (“Invion” or “the Company”) announces that Invion’s Chief Operating Officer, Craig Newton will transition to the role of Chief Executive Officer effective 1 November 2019. Dr Greg Collier will retire as MD and CEO, effective 31 October 2019. Dr Collier will remain on the Board of Invion as a Non-Executive Director. Dr Collier joined Invion in May 2013. During his tenure as MD and CEO, Dr Collier has overseen the development and spin-out of the Company’s respiratory assets, and most recently the successful transaction with The Cho Group to acquire the Australian and New Zealand commercialisation rights for PhotosoftTM technology. Invion leads the global development of the PhotosoftTM technology under the auspices of an R&D services agreement between the Company and The Cho Group, an agreement that has seen significant advances over the past 15 months in preparation for clinical trials starting in Q4 2019. Dr Collier is leaving his executive role to focus on other areas and companies of interest. Dr Collier said “Invion’s Board and management have worked tirelessly in the 18 months since the PhotosoftTM transaction to build and resource a company that is ready for the next stage of product development. “Invion is now in a strong position with a clear focus, the right team, and a sound funding plan. I am confident this is the right time for a succession in leadership.” Craig Newton joined Invion as Chief Operating Officer in April 2018. Since that time, Craig has recruited a strong and experienced clinical development team. Craig has over 30 years of experience in senior business and operational roles gained at various leading global companies including CSL, Serono UK, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals. Invion Chairman, Thian Chew, thanked Dr Collier for his contribution to the Company. “Invion has been very fortunate to have a leader of Greg’s calibre for over six years. Greg’s significant experience in drug development through to FDA approval, commercial acumen and depth of scientific knowledge has been a true asset. The Board is pleased that Greg has agreed to remain as a Non-executive Director following his retirement.” “The Board is delighted to have secured Craig Newton as CEO, his expertise and enthusiasm have been vital over the past 15 months, and we look forward to the continuing success of Invion as Craig leads the ongoing development of the PhotosoftTM technology as a treatment for a range of cancers.” ENDS Investor enquires Managing Director & CEO, Dr Greg Collier T: +61 3 9081 6005 E: investor@inviongroup.com Invion Limited ABN 76 094 730 417 722 High Street, East Kew, VIC 3102 Australia P: +61 3 9081 6005 W: www.inviongroup.com About Invion Invion is a drug delivery company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, The Cho Group, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). About Photodynamic Therapy (PDT) Invion is developing PhotosoftTM technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes. Invion Limited ABN 76 094 730 417 722 High Street, East Kew, VIC 3102 Australia P: +61 3 9081 6005 W: www.inviongroup.com